Vanqua Bio is helping usher in a new era of hope for the millions of people living with neurodegenerative diseases. Our unique drug-development approach is designed to overcome longstanding challenges in the neuroscience field by capitalizing on the power of human genetics to identify genes that cause or increase the risk of neurodegenerative disease. We leverage novel, proprietary research tools and in vitro modeling of disease, based on patient-derived neuronal cells, to develop transformative therapies that slow or stop the progression of Parkinson’s disease (PD), Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Gaucher disease (GD). 

Biotechnology

Vanqua Bio

Jim Sullivan

Jesse Cedarbaum

Omer Siddiqui

Daniel Ysselstein

Jack Beyer

Kevin Hunt

The Leadership Team at Vanqua Bio is responsible for shaping the strategic direction of the company, guiding its mission to develop innovative therapies for neurodegenerative diseases. Comprising key executives, including the CEO, Chief Business Officer, and Chief Scientific Officer, this team collaborates to align research goals with business objectives, drives partnerships, and ensures that the company's groundbreaking approaches effectively address the challenges within the neuroscience field.

Leadership Team

Research and Development

Research and Development Team

Leadership Team

About

Team members

Other teams at Vanqua Bio

Research and Development

Research and Development Team